A novel investigational luteinizing hormone-releasing hormone antagonist.

The primary endpoint is the incidence of perhaps drug-related adverse events. Cetrorelix is part of AEterna Zentaris’ LHRH antagonist therapeutic approach which has demonstrated in Phase 2 studies to provide fast and long-lasting alleviation of BPH symptoms while getting well tolerated, with a minimal incidence of sexual unwanted effects. Cetrorelix peptide-based drugs were developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, of the U currently.S. Veterans Administration in Miami. Cetrorelix acetate is normally marketed under the brand Cetrotide, the initial LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs in European countries, the U.S.Patients who did have a response in week 39 had the study medications withdrawn and were observed through week 65. Etanercept and placebo injections were stopped at week 39; methotrexate and placebo capsules were tapered over the course of 2 to 4 weeks. Individuals and investigators remained unaware of the study-group assignments before end of the analysis . Study Oversight The institutional review board or ethics committee at each participating center approved the analysis protocol . The analysis was conducted in accordance with the ethical concepts of the Declaration of Helsinki and the Good Clinical Practice recommendations of the International Conference on Harmonisation.